Evidence map›Paper›PMID 41847702›Full record

ReviewFrontiers in oncology2026

TK1 in gastric cancer: Helicobacter pylori-driven oncogenesis biomarker, utility, and emerging targeted therapies.

Zi-Xuan Zheng, Lu Yang, Jun-Tong Chen, Yan Zeng, Shi-Xue Dai, Shi-Jie Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zi-Xuan Zheng *The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Lu Yang *The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Jun-Tong Chen *The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Yan ZengDepartment of Gastroenterology, Geriatric Center, National Regional Medical Center, Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou Municipal Hospital, Ganzhou, Jiangxi, China.
Shi-Xue DaiDepartment of Gastroenterology, Guangdong Provincial Geriatrics Institute, National Key Clinical Specialty, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Shi-Jie LiuDepartment of Gastroenterology, Geriatric Center, National Regional Medical Center, Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou Municipal Hospital, Ganzhou, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a leading cause of cancer-related mortality among gastrointestinal malignancies, gastric carcinoma (GC) necessitates enhanced molecular diagnostic paradigms for early intervention. The thymidine kinase enzymatic family, particularly thymidine kinase 1 (TK1, EC 2.7.1.21), serves as an enzymatic orchestrator of deoxyribonucleotide salvage pathways critical for genomic integrity maintenance, and its oncogenic overexpression acts in concert with

Indexed as

gastric cancerHelicobacter pyloriserum biomarkertargeted therapiesthymidine kinases

Identifiers

PMID41847702
PMCPMC12990211

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.